CD44 expression in benign, premalignant, and malignant ovarian neoplasms: Relation to tumour development and progression

Journal of Pathology

Volumn 189, Issue 3, 1999, Pages 326-337

  Saegusa, Makoto ^a   Machida, Daisuke ^a   Hashimura, Miki ^a   Okayasu, Isao ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CD44s; CD44v3; CD44v6; Cystadenoma; Immunohistochemistry; LMP tumour; Ovarian carcinoma; Prognosis

Indexed keywords

HERMES ANTIGEN; HORMONE RECEPTOR; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SOUTHERN BLOTTING; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; ANTIGENS, NEOPLASM; CYSTADENOMA; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; OVARIAN NEOPLASMS; PRECANCEROUS CONDITIONS; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0032856835     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199911)189:3<326::AID-PATH425>3.0.CO;2-6     Document Type: Article

References (32)

1. Jalkenen S, Steers AC, Fox RI, Butcher EC. A distinct endothelial cell recognition system that controls lymphocyte traffic into inflamed synovium. Science 1986; 233: 556-558.
2. Screaton GR, Bell MV, Jackson DG, et al. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992; 89: 12160-12164.
3. Salles G, Zain M, Jiang WM, Boussiotis VA, Shipp MA. Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies. Blood 1993; 82: 3539-3547.
4. Gunthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65: 13-24.
5. Seiter S, Arch R, Reber S, et al. Prevention of tumor metastatic formation by anti-variant CD44. J Exp Med 1993; 177: 443-455.
6. Zeimet AG, Widschwendter M, Uhl-Steidl M, et al. High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer. Br J Cancer 1997; 76: 1646-1651.
7. Uhl-Steidl M, Muller-Holzner E, Zeimet AG, et al. Prognostic value of CD44 splice variant expression in ovarian cancer. Oncology 1995; 52: 400-406.
8. Cannistra SA, Abu-Jawdeh G, Niloff J, et al. CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors. J Clin Oncol 1995; 13: 1912-1921.
9. Saegusa M, Hashimura M, Okayasu I. CD44 expression in normal hyperplastic, and malignant endometrium. J Pathol 1998; 184: 297-306.
10. Saegusa M, Okayasu I. Up-regulation of CD44 variant exon expression in endometrial carcinomas: analysis of mRNA and protein isoforms, and relation to clinicopathological factors. Jpn J Cancer Res 1998; 89: 291-298.
11. Bell DA, Scully RE. Early de novo ovarian carcinoma: a study of fourteen cases. Cancer 1994; 73: 1859-1864.
12. Puls LE, Powell DE, DePriest PD, et al. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol 1992; 47: 53-57.
13. Mandai M, Konishi I, Kuroda H, et al. Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology. Hum Pathol 1998; 28: 34-40.
14. Darai E, Walker-Combrouze F, Fauconnier A, et al. Analysis of CD44 expression in serous and mucinous borderline tumours of the ovary: comparison with cystadenomas and overt carcinomas. Histopathology 1998; 32: 151-159.
15. Wheatley SC, Isacke CM, Crossley PH. Restricted expression of the hyaluronan receptor, CD44, during postimplantation mouse embryogenesis suggests key roles in tissue formation and patterning. Development 1993; 119: 295-306.
16. Fasano M, Sabatini MT, Wieczorek R, et al. CD44 and its v6 spliced variant in lung tumors: a role in histogenesis? Cancer 1997; 80: 34-41.
17. Heider K-H, Ratschek M, Zatloukal K, Adolf GR. Expression of CD44 isoforms in human renal cell carcinomas. Virchows Arch 1996; 428: 267-273.
18. Soukka T, Salmi M, Joensuu H, et al. Regulation of CD44v6-containing isoforms during proliferation of normal and malignant epithelial cells. Cancer Res 1997; 57: 2281-2289.
19. Noordzij MA, van Steenbrugge GJ, Verkaik NS, Schroder FH, van der Kwast TH. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Clin Cancer Res 1997; 3: 805-815.
20. Sugino T, Gorham H, Yoshida K, et al. Progressive loss of CD44 gene expression in invasive bladder cancer. Am J Pathol 1996; 149: 873-882.
21. Aruffo A, Stamenkovic M, Melnick CB, Underhill B, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990; 61: 1303-1313.
22. Neame SJ, Isacke CM. The cytoplasmic tail of CD44 is required for basolateral localization in epithelial MDCK cells but does not mediate association with the detergent-insoluble cytoskeleton of fibroblasts. J Cell Biol 1993; 121: 1299-1310.
23. Strobel T, Swanson L, Cannistra SA. In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. Cancer Res 1997; 57: 1228-1232.
24. Gotley DC, Fawcett J, Walsh MD, et al. Alternatively spliced variants of the cell adhesion molecule CD44 and tumour progression in colorectal cancer. Br J Cancer 1996; 74: 342-351.
25. Tran TA, Kallakury BVS, Sheehan CE, Ross JS. Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas. Hum Pathol 1997; 28: 809-814.
26. Roca X, Mate JL, Ariza A, et al. CD44 isoform expression follows two alternative splicing pathways in breast tissue. Am J Pathol 1998; 153: 183-190.
27. Woodman AC, Sugiyama M, Yoshida K, et al. Analysis of anomalous CD44 gene expression in human breast, bladder, and colon cancer and correlation of observed mRNA and protein isoforms. Am J Pathol 1996; 149: 1519-1530.
28. Gorham H, Sugino T, Woodman AC, Tarin D. Cellular distribution of CD44 gene transcripts in colorectal carcinomas and in normal colonic mucosa. J Clin Pathol 1996; 49: 482-488.
29. Slotman BJ, Nauta JJP, Rao BR. Survival of patients with ovarian cancer: apart from stage and grade, tumor progesterone receptor content is a prognostic indicator. Cancer 1990; 66: 740-744.
30. Isola J, Kallioniemi O-P, Korte J-M, et al. Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival. J Pathol 1990; 162: 295-301.
31. Rose PG, Reale FR, Longcope C, Hunter RE. Prognostic significance of estrogen and progesterone receptors in epithelial ovarian cancer. Obstet Gynecol 1990; 76: 285-263.
32. Harding M, Cowan S, Hole D, et al. Estrogen and progesterone receptors in ovarian cancer. Cancer 1990; 65: 486-491.